Blue Arbor's Implanted Electrodes Aim for a Natural Grip in Prosthetic Arms

The promise of a robotic prosthetic arm has long been shadowed by a stubbornly analog control problem. For a person with upper-limb loss, the dream of a natural, simultaneous movement of fingers and wrist often collides with the limited signals captured by surface electrodes on the skin. Blue Arbor Technologies, an Ann Arbor-based medical device startup, is betting the solution lies not on the surface, but beneath it.

Founded in 2015, the company is developing the RESTORE Neuromuscular Interface System, an implanted device designed to create a more direct and intuitive link between a patient's nervous system and a commercially available robotic prosthesis. The system's core is a small, implanted sensing unit connected to electrodes placed within the residual muscles. These electrodes pick up the nuanced electrical signals the brain still sends, which are then wirelessly transmitted and decoded to control a prosthetic hand or arm [PERPLEXITY SONAR PRO BRIEF]. The goal is to move beyond sequential, single-motion commands toward the independent, simultaneous control that defines a natural grip [PERPLEXITY SONAR PRO BRIEF].

A Decade of Research, Packaged for Patients

The company's foundation is less a traditional startup narrative and more the commercialization of a 17-year academic research program. The three co-founders,Dr. Paul Cederna (President), Dr. Theodore Kung (Chief Medical Officer), and Dr. Alex Vaskov (Chief Technology Officer),have collectively secured more than $60 million in direct research grant funding and authored over 200 peer-reviewed publications on the underlying science [Today's Medical Developments, February 2026] [EQS News, February 2026]. Dr. Cederna, a biomedical engineer and plastic surgeon at the University of Michigan, has personally led the research initiative since 2007 [PERPLEXITY SONAR PRO BRIEF]. This grants-based runway provided the rare luxury of deep, foundational development before seeking significant venture capital.

The transition from lab to clinic is now underway. In April 2024, the U.S. Food and Drug Administration granted the RESTORE system Breakthrough Device Designation, a status that can expedite the development and review process for devices that address unmet medical needs [BioSpace, April 2024]. The FDA also enrolled RESTORE in its Total Product Life Cycle Advisory Program pilot, offering early, interactive feedback [Blue Arbor Technologies, April 2024]. Clinically, Blue Arbor has reported completing its first-in-human procedure at the Medical University of Vienna in December 2025, followed by a second procedure at the same site [Medical Design & Outsourcing, February 2026] [ODT, October 2026].

The Strategic Bet from Ottobock

Blue Arbor's most significant validation to date comes not from a traditional venture fund, but from a strategic partner deeply embedded in its target market. In February 2026, the company announced a $5 million investment and strategic partnership with Ottobock, a global leader in prosthetic and orthotic devices [Blue Arbor Technologies, February 2026]. That relationship deepened in October 2026 when Ottobock led a further $10.5 million Series A extension, bringing the total disclosed Series A funding to $15.5 million [Business Wire, October 2026].

This capital is earmarked for critical next steps: advancing U.S. clinical studies, continuing product development, and pursuing an FDA Investigational Device Exemption to begin formal clinical trials in the United States [Business Wire, October 2026]. The partnership with Ottobock is a classic strategic wedge, providing not just capital but also potential pathways to manufacturing, clinical networks, and, ultimately, commercial distribution.

Role	Name	Key Background
President & Co-Founder	Dr. Paul Cederna	Robert Oneal Professor of Plastic Surgery and Biomedical Engineering at University of Michigan; over $45M in direct research funding [Behind the Microscope, February 2022] [Equilar ExecAtlas, Retrieved 2026].
Chief Medical Officer & Co-Founder	Dr. Theodore Kung	Clinical co-founder specializing in the surgical application of the interface technology [ODT, February 2026].
Chief Technology Officer & Co-Founder	Dr. Alex Vaskov	Technical co-founder leading the engineering and signal processing development [ODT, February 2026].

Navigating the Clinical and Commercial Pathway

The road from two human implants to a commercially available product is long, expensive, and fraught with regulatory complexity. The company's near-term milestones are clear: progressing through the FDA's IDE process and initiating U.S. clinical trials. The Breakthrough Device status helps, but it does not guarantee approval. The clinical data must convincingly demonstrate that the benefits of an invasive, implanted system,requiring surgery and carrying associated risks,significantly outweigh those of existing surface-based control technologies.

Furthermore, Blue Arbor is not building the prosthetic limbs themselves. Its business model is to provide the control interface, the "brain" of the operation, that integrates with advanced robotic prosthetics from partners like Ottobock [PERPLEXITY SONAR PRO BRIEF]. This creates a symbiotic but dependent relationship. Success hinges on smooth integration and proving that the RESTORE system can unlock the full potential of next-generation prosthetic hardware in a way that resonates with clinicians, payers, and, most importantly, patients.

The patient population here is individuals with upper-limb loss, a group for whom regaining functional hand and arm movement can be profoundly life-altering. The current standard of care for controlling myoelectric (muscle-signal) prostheses relies on surface electrodes placed on the skin over residual muscles. This approach is non-invasive but can be limited by signal quality, consistency, and the ability to decode only a few distinct commands at a time, often forcing users into slow, sequential motions. For many, the prosthetic becomes a tool for specific tasks rather than a natural extension of the body. Blue Arbor's bet is that by moving the sensors inside the body, closer to the source of the signal, they can provide the fidelity needed for that natural extension, turning advanced robotic hardware into a truly intuitive limb.

Sources

1. [Business Wire, October 2026] Blue Arbor Technologies Raises $10.5 Million Series A Led by Ottobock | https://www.businesswire.com/news/home/20261028723707/en/
2. [Blue Arbor Technologies, February 2026] Blue Arbor Technologies Announces Strategic Partnership with Ottobock and $5 Million Investment | https://bluearbortech.com/blue-arbor-technologies-announces-strategic-partnership-with-ottobock-and-5-million-investment-to-advance-restore-neuromuscular-interface-system/
3. [Today's Medical Developments, February 2026] Founders have collectively secured more than $60 million in direct research grant funding | Source article on Blue Arbor
4. [EQS News, February 2026] Ottobock invests in future technology from Blue Arbor Technologies Inc. | https://www.eqs-news.com/news/corporate-news/ottobock-invests-in-future-technology-from-blue-arbor-technologies-inc/6b88f9a6-47e5-4e10-b975-79e1022e43fd_en
5. [PERPLEXITY SONAR PRO BRIEF] Product description and company overview
6. [BioSpace, April 2024] Blue Arbor Technologies Receives FDA Breakthrough Device Designation | https://www.biospace.com/blue-arbor-technologies-receives-fda-breakthrough-device-designation-and-tap-enrollment-for-the-restore-neuromuscular-interface-system
7. [Blue Arbor Technologies, April 2024] FDA Breakthrough Device Designation and TAP Enrollment announcement | https://bluearbortech.com/blue-arbor-technologies-receives-fda-breakthrough-device-designation-and-tap-enrollment-for-the-restore-neuromuscular-interface-system/
8. [Medical Design & Outsourcing, February 2026] Report on first-in-human procedure | https://www.medicaldesignandoutsourcing.com/blue-arbor-limb-prosthetics-control-implants-exoskeleton/
9. [ODT, October 2026] Report on second human implantation | https://www.odtmag.com/breaking-news/blue-arbor-technologies-nets-5-million-investment-for-neuromuscular-interface-system/
10. [Behind the Microscope, February 2022] Background on Dr. Paul Cederna | https://podcasts.apple.com/us/podcast/paul-cederna-md-endless-opportunities-for-surgeon-scientists/id1484074780?i=1000550667081
11. [Equilar ExecAtlas, Retrieved 2026] Research funding for Dr. Paul Cederna
12. [ODT, February 2026] Team roles for Dr. Theodore Kung and Dr. Alex Vaskov | https://www.odtmag.com/breaking-news/blue-arbor-technologies-nets-5-million-investment-for-neuromuscular-interface-system/